Low-dose lung radiotherapy for COVID-19 lung disease: a preclinical efficacy study in a bleomycin model of pneumonitis.
Low-dose whole lung radiotherapy (LDLR) has been proposed as a treatment for patients with acute respiratory distress syndrome associated with SARS-CoV-2 infection and clinical trials are underway. There is an urgent need for preclinical evidence to justify this approach and inform dose, scheduling and mechanisms of action.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Mark R Jackson, Katrina Stevenson, Sandeep K. Chahal, Emer Curley, George E Finney, Rodrigo Gutierrez-Quintana, Evarest Onwubiko, Angie Rupp, Karen Strathdee, Karin Williams, Megan KL MacLeod, Charles McSharry, Anthony J Chalmers Tags: Biology Contribution Source Type: research
More News: Biology | Cancer & Oncology | Clinical Trials | COVID-19 | Physics | Radiology | Respiratory Medicine | SARS | Study